Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
A British study has found that nintedanib, a drug used to treat cancer, can slow the progression of idiopathic pulmonary fibrosis (IPF).
The research, published in the New England Journal of Medicine, involved two clinical trials involving 1,066 people with IPF. Participants were selected at random to either take 150mg of nintedanib or a dummy drug (placebo) twice per day throughout the course of the trial.
The drug was found to reduce the annual decline in breathing capacity typically seen in people with IPF, slowing the progression of the disease.
These results could be promising for the development of IPF treatment options, which are currently very limited and not available throughout Europe.
Read the original news article.
The European Lung Foundation has been working with people with IPF and patient organisations to help update the 2011 European Respiratory Society guidelines, by adding new research on treatments and the patients’ perspective on the condition
Focus groups have been held with patients and carers across Europe to give feedback on key issues in IPF treatment and management, and highlight the patients’ priorities.
This feedback will then be included in the final guideline document, with a response from the Task Force to the key issues raised by patients.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description